Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.

By J. Chastre, M. Wolff, J. Fagon, S. Chevret, F. Thomas, D. Wermert, E. Clementi, Jésus Gonzalez, D. Jusserand, P. Asfar and 3 more. Journal of the American Medical Association (JAMA), 2003

1,317 citations recorded by the source corpus.

Subfields: Critical Care and Intensive Care Medicine, Molecular Medicine, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/77151e06dd012c2bf38af907844873aef092c517

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Critical Care and Intensive Care Medicine

1. 古谷 良輔
2. 山口 和将
3. C. MacDougall
4. S. Cosgrove
5. Mitchell M. Levy
6. Marin Kollef
7. J. Bartlett
8. T. Dellit

In Molecular Medicine

1. T. Dellit
2. S. Cosgrove
3. 古谷 良輔
4. 山口 和将
5. Marin Kollef
6. P. Plésiat
7. P. Nordmann
8. L. Poirel

In Pulmonary and Respiratory Medicine

1. Marin Kollef
2. A. Anzueto

Citations in the corpus

• Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. (2016, background): “Chastre et al, 2003 [127] Adults with VAP 8 vs 15 Mortality, recurrent infections”
• Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (2007, background): “aeruginosa pneumonia led to relapse more commonly than did a 15-day course of therapy [279].”
• Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. (2008, background): “Patients with ventilator-associated pneumonia, for example, are equally well treated when they receive an 8-day treatment as compared with a 15-day course of antibiotics (5).”
• The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections (2012, methodology): “courses shorter than those historically pre- aeruginosa Pneumonia scribed,[103,105,106] help to emphasise the importance”
• Guidelines for the management of adult lower respiratory tract infections - Full version (2011, neutral): “aeruginosa and other non-fermenters, clinicians must be aware of an increased risk of relapses [416].”
• Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. (2007, background): “An 8-day period of treatment does not worsen the outcome of patients suffering from ventilator-associated pneumonia [118], but saves money, reduces ecological pressure, and diminishes side-effects [98].”
• General Principles of Antimicrobial Therapy (2011, background): “For example, evidence supports limiting treatment of uncomplicated UTI in women to 3 days,(25) community-acquired pneumonia to 5 days,(26) and ventilator-associated pneumonia to 8 days.(27) However, when administering abbreviated treatment courses, it is important for clinicians to ensure that their”
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (2008, methodology): “aeruginosa, and that the patient has a good clinical response with resolution of clinical features of infection (Level I) (210).”